and at a the best time possible as Big pharma gear up for a M&A season feast
Pharmaceutical and biotech companies spent $85bn on acquisitions in the first five months of the year, marking a dramatic recovery in dealmaking as they seek to replenish their drug pipelines.The surge in M&A, compared to just $35.6bn in deals in the same period of 2022 and $49.1bn the year before, according to Stifel, an investment bank, is being fuelled by large cash reserves amassed by Big Pharma during the coronavirus pandemic and investor concerns about future growth prospects.
And pharmaceutical companies have to buy. Many, including Merck, Bristol Myers Squibb (BMY) and AbbVie (ABBV), are facing current or looming competition for their biggest blockbuster drugs as patents
More than just volume and liquidity in H2 2023
